AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05519813
Drug: Pioglitazone Hydrochloride And Metformin Hydrochloride Tablets
RxNorm normalized name: metformin and pioglitazone
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Use Pioglitazone Hydrochloride And Metformin Hydrochloride Tablets for 3 months to treat PCOS
Trial: NCT05444569
Drug: Liraglutide
RxNorm normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered SC.
Trial: NCT05239663
Drug: Ganglioside-Monosialic Acid
RxNorm normalized name: IMMUNOGLOBULIN G1, ANTI-(GANGLIOSIDE GD2) (HUMAN-MUS MUSCULUS MONOCLONAL CH14.18 HEAVY CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL CH14.18 LIGHT CHAIN, DIMER
DrugBank: Dinutuximab (DB09077)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Standard (neo)adjuvant chemotherapy (Taxanes combined with cyclophosphamide or doxorubicin combined with cyclophosphamide followed by taxanes) plus Ganglioside-Monosialic Acid 100mg+250ml normal saline (NS)
Trial: NCT05239663
Drug: 250ml normal saline (NS)
RxNorm normalized name: NS-2
DrugBank: Reproxalap (DB16688)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard (neo)adjuvant chemotherapy (Taxanes combined with cyclophosphamide or doxorubicin combined with cyclophosphamide followed by taxanes) plus 250ml normal saline (NS)
Trial: NCT06124066
Drug: Mirabegron 50 MG
RxNorm normalized name: mirabegron 50 MG
DrugBank: Mirabegron (DB08893)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The participants were given mirabegron 50 mg or tamsulosin 0.4 mg and filled in the Ureteral Stent Symptom Questionnaire (USSQ), filled in directly when the patient arrived or by telephone.
Trial: NCT05263609
Drug: Axitinib
RxNorm normalized name: Axitinib
DrugBank: Axitinib (DB06626)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: If pembrolizumab infusions alone do not reduce the patient's tumor size by at least 60%,the patient will be placed in Arm B and start axitinib in addition to continuing pembrolizumab therapy (see Arm B).
Trial: NCT05263609
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: If pembrolizumab results in a reduction in tumor size that is greater than 60%, the patient will be placed in Arm A and continue pembrolizumab infusions (see Arm A).
Trial: NCT00002015
Drug: Ganciclovir
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02055196
Drug: irinotecan hydrochloride
RxNorm normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04258072
Drug: Vactosertib
RxNorm normalized name: Vactosertib
DrugBank: Vactosertib (DB15310)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vactosertib: 50-mg white round film-coated tablets containing excipients (lactose monohydrate Fastflo 316, microcrystalline cellulose Avicel PH 102, crospovidone Kollidon CL-F, povidone Kollidon 30, magnesium stearate, opadry white) and active pharmaceutical ingredient (N-((4-(\[1,2,4\]triazolo\[1,5-a\]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl)methyl)-2-fluoroaniline), 10% (w/w) of total weight
Trial: NCT04670120
Drug: Pyrifazimine (TBI-166)
RxNorm normalized name: Pyrilamine
DrugBank: Pyrifazimine (DB18898)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The new drug pyrifazimine (previous name: TBI-166) is obtained by retaining the key skeleton of the lead drug clofazimine which can exert its efficacy and modification by introducing moderate polar groups structural. While the drug has strong activity against tuberculosis-sensitive bacteria and drug-resistant bacteria in vivo and in vitro, its pharmacokinetic properties and skin staining side effects have been significantly improved compared with the lead drugs, so that the drug can achieve the goal that reducing fat solubility, accelerating metabolism in the body, reducing skin staining and reducing side effects.~In November 2016, the new anti-drug-resistant tuberculosis drug pyrifazimine and its tablets obtained the drug clinical approval issued by the CFDA, and were approved the clinical stage research that development of drug-resistant tuberculosis adaptation.
Trial: NCT05502627
Drug: 0.25% lemon grass oil mouthwash
DrugBank: Lemon (DB10538)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25% lemon grass oil mouth wash given twice daily for fourteen days to the patients of chronic periodontitis after scaling in experimental group and in control group only scaling was done.
Trial: NCT06401707
Drug: Perampanel
RxNorm normalized name: Perampanel
DrugBank: Perampanel (DB08883)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Perampanel is a non-competitive AMPA glutamate receptor antagonist.
Trial: NCT06227325
Drug: RC48 combined with Sintilimab and XELOX
RxNorm normalized name: miconazole
DrugBank: Sintilimab (DB15765)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: RC48: 2.5 mg/kg, iv, d1, repeat every 2 weeks; Sintilimab: 200mg, iv, d1, repeat every 3 weeks; XELOX: Oxaliplatin 130mg/m2, iv, d1；Capecitabine1000 mg po, bid, d1-14, repeat every 3 weeks
Trial: NCT05985863
Drug: hUC-MSC
RxNorm normalized name: Allogeneic bone marrow-derived mesenchymal stromal cells (MSCs)
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hUC-MSC (1.5×10\^8 cells/time, Peripheral IV, at week0, week1 and week2)
Trial: NCT05985863
Drug: hUC-MSC_Prolonged
RxNorm normalized name: Allogeneic bone marrow-derived mesenchymal stromal cells (MSCs)
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hUC-MSC (1.5×10\^8 cells/time, Peripheral IV, at week4 and week5)
Trial: NCT06034418
Drug: Nerve block with 1 cc betamethasone and 1 cc 1% lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In the procedures to be performed under fluoroscopy, vascular structures will be detected primarily by ultrasonography for safety purposes. A standard RF device will be used for the process. A 22-gauge and 10 cm straight radiofrequency cannula with 1 cm active tip will be used. For each nerve, sensory stimulation will be performed at 50 Hz and the patient will be expected to feel numbness and tingling with a maximum 0.7 V. Motor stimulation will be at 2 Hz and no muscle contraction up to 2 V is expected. Following the appropriate cannula placement, patients will be injected with 1 cc betamethasone and 1 cc 1% lidocaine for each nerve. A total of 2 cc volume will be injected for each nerve.
Trial: NCT05022160
Drug: pudendal nerve block
RxNorm normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All patients in the study group will receive bilateral pudendal nerve block at the end of surgery, with help of landmark technique, using 0.5% bupivacaine
Trial: NCT04843319
Drug: VERU-100
RxNorm normalized name: Panax verus root
DrugBank: Ginseng (DB01404)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GnRH antagonist
Trial: NCT05469646
Drug: BI 1819479
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 1819479
Trial: NCT04892069
Drug: Insulin Degludec/Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: All patients have been treated at the discretion of the treating physician in accordance with the Ryzodeg® label in Lebanon. Decision to initiate treatment with commercially available Ryzodeg® has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in this study.
Trial: NCT04559230
Drug: Sacituzumab Govitecan
RxNorm normalized name: sacituzumab govitecan
DrugBank: Sacituzumab govitecan (DB12893)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sacituzumab Govitecan will be administered by IV infusion over 3 hours for first administration and over 1 hour if tolerated. Subjects will be allowed to continue treatment until they have evidence of significant treatment-related toxicity or progressive disease.
Trial: NCT05514041
Drug: Varenicline solution
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: OC-01 nasal spray 0.03 mg
Trial: NCT05514041
Drug: Placebo nasal spray (OC-01 Vehicle Nasal Spray)
RxNorm normalized name: OCE-205
DrugBank: OCE-205 (DB17617)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo nasal spray (OC-01 Vehicle Nasal Spray)
Trial: NCT05062759
Drug: Tezepelumab
RxNorm normalized name: Tezepelumab
DrugBank: Tezepelumab (DB15090)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 210 mg SC injection Q4W.
Trial: NCT06386146
Drug: JAB-30355
RxNorm normalized name: JAB-3068
DrugBank: JAB-3068 (DB17131)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration
Trial: NCT05043740
Drug: Repatha or Praluent
RxNorm normalized name: Repatha
DrugBank: Evolocumab (DB09303)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Evolocumab (Repatha®) 140 mg or Alirocumab (Praluent) 75mg every two weeks, first subcutaneous injection at the time of randomization, followings during 12 months
Trial: NCT04718922
Drug: Chlorhexidine Gluconate 0.12 % Mouthwash
RxNorm normalized name: chlorhexidine gluconate 0.12 % Mouthwash
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intervention with chlorhexidine mouthrinse will be performed approximately 10 min before the start of EBUS-TBNA
Trial: NCT06293742
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam will be administered orally.
Trial: NCT06293742
Drug: Digoxin
RxNorm normalized name: Digoxin
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Digoxin will be administered orally.
Trial: NCT06293742
Drug: Atorvastatin
RxNorm normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atorvastatin will be administered orally.
Trial: NCT04752371
Drug: Camoteskimab (CERC-007, AVTX-007, AEVI-007)
RxNorm normalized name: CERCIS SILIQUASTRUM WHOLE
DrugBank: Camoteskimab (DB18876)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) Infusion
Trial: NCT04738292
Drug: Onapristone
RxNorm normalized name: Onapristone
DrugBank: Onapristone (DB12637)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Onapristone is a type I antiprogestin which prevents the PgR from dimerizing and blocks ligand induced protein kinase-mediated phosphorylation of the PgR.
Trial: NCT04738292
Drug: Fulvestrant
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fulvestrant binds, blocks and degrades the ER, completely inhibiting ER signaling.
Trial: NCT05343325
Drug: Tislelizumab
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tislelizumab: 200 mg D1, Q3W for two cycles. Albumin-bound paclitaxel: 100mg/m2, D1, D8, D15, Q3W for two cycles. Cisplatin: 25mg/m2, D1, D8, D15, Q3W for two cycles.
Trial: NCT05253495
Drug: DOC Group C
RxNorm normalized name: meningococcal group C polysaccharide
DrugBank: Meningococcal polysaccharide vaccine group C (DB13890)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cyclophosphamide x 1, dexamethasone x 5; vincristine x1; IT triples x 3
Trial: NCT00000638
Drug: Isoniazid
RxNorm normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00000638
Drug: Pyrazinamide
RxNorm normalized name: Pyrazinamide
DrugBank: Pyrazinamide (DB00339)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05253495
Drug: Pv-R CYVE-MTX 1 and 2
RxNorm normalized name: MTX
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Polatuzumab Vedotin x 1; Rituximab x 1; Cytarabine x 5; Etoposide x4; high dose cytarabine x4; high dose methotrexate x 1 (only consolidation 1); IT triples x 2 (only 1 in consolidation 2)
Trial: NCT05253495
Drug: MAD CP
RxNorm normalized name: methylcellulose (1500 CPS)
DrugBank: Methylcellulose (DB11228)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dexamethasone x1; polatuzumab vedotin x 1; cyclophosphamide x 2; doxorubicin x 1; high dose methotrexate x 1; IT triples x 1
Trial: NCT05253495
Drug: Pv-Cytarabine/etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: polatuzumab vedotin x 1; cytarabine x 5; etoposide x 3;
Trial: NCT05253495
Drug: AD CP
RxNorm normalized name: methylcellulose (1500 CPS)
DrugBank: Methylcellulose (DB11228)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: polatuzumab vedotin x 1; cyclophosphamide x2; doxorubicin x 2;
Trial: NCT04520490
Drug: Exenatide 2 mg [Bydureon]
RxNorm normalized name: exenatide 2 MG [Bydureon]
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly injections of active drug.
Trial: NCT00000638
Drug: Rifampin
RxNorm normalized name: Rifampin
DrugBank: Rifampin (DB01045)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05638282
Drug: Cendakimab
RxNorm normalized name: Cendakimab
DrugBank: Cendakimab (DB18427)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT05292092
Drug: Essential pro
RxNorm normalized name: Climara Pro
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients in whom treatment with (Essential Pro) has been attempted
Trial: NCT05382143
Drug: Atosiban
RxNorm normalized name: atosiban
DrugBank: Atosiban (DB09059)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Pilot study
Trial: NCT05720637
Drug: SSRI
RxNorm normalized name: SSRI - Selective serotonin re-uptake inhibitor
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SSRIs antidepressants, including fluoxetine, paroxetine, sertraline, citalopram, etc., will be administered at oral doses determined by the psychiatrist. Once daily for the duration of the trial.
Trial: NCT06155994
Drug: 68Ga-DOTA-MGS5
RxNorm normalized name: 68Ga-DOTATATE
DrugBank: Dotatate gallium Ga-68 (DB13925)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous administration
Trial: NCT06306339
Drug: Burfiralimab
RxNorm normalized name: Burfiralimab
DrugBank: Burfiralimab (DB18935)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Humanized monoclonal antibody.
Trial: NCT04790539
Drug: SHR-1210
RxNorm normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR-1210 is a humanized anti-PD-1 IgG4 monoclonal antibody
Trial: NCT05619328
Drug: Vitamin B combination tablet
RxNorm normalized name: VITAMIN B
DrugBank: Cyanocobalamin (DB00115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Once daily, with some liquid with or after a meal
Trial: NCT04867928
Drug: Venetoclax+azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: subjects will receive venetoclax 400 mg orally QD on Days 1 - 28 plus azacitidine 75 mg/m2 SC or IV daily for 7 days. Cycle Length - 28 Days. . Subjects will continue treatment until subsequent alloSCT.
Trial: NCT00016536
Drug: Naphthalene 2-sulfonate polymer
RxNorm normalized name: Naphthalene 2-sulfonate polymer
DrugBank: PRO 2000 (DB05385)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00016536
Drug: Carbopol polymer
RxNorm normalized name: Carbopol polymer
DrugBank: Carbopol 974P (DB05384)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05494528
Drug: Ropeginterferon alfa-2b
RxNorm normalized name: Ropeginterferon alfa-2b
DrugBank: Ropeginterferon alfa-2b (DB15119)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ropeginterferon alfa-2b 450 µg subcutaneous injection every two weeks
Trial: NCT05494528
Drug: Entecavir
RxNorm normalized name: Entecavir
DrugBank: Entecavir (DB00442)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Entecavir 0.5 mg once per day
Trial: NCT04590118
Drug: it-hMSC
RxNorm normalized name: IT-139
DrugBank: IT-139 (DB17145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intravenous infusion of it-hMSC for ischemic stroke patients
Trial: NCT04530474
Drug: Ivermectin Pill
RxNorm normalized name: ivermectin Pill
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ivermecin as a one-time dose
Trial: NCT03567824
Drug: Magnesium L-lactate dihydrate
RxNorm normalized name: Magnesium L-lactate Dihydrate
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Magnesium L-lactate dihydrate 10 mEq extended release caplets
Trial: NCT06402019
Drug: Dexmedetomidine in 0.9 % NaCl 20 Mcg/5 mL (4 Mcg/mL) INTRAVEN SYRINGE (ML)
RxNorm normalized name: dexmedetomidine in 0.9 % NaCl 20 mcg/5 mL (4 mcg/mL) INTRAVEN SYRINGE (ML)
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Group went under multiple sessions of Dexmedetomidine infusion for 10 sessions; The infusion was provided under non-invasive monitoring for heart rate (HR) and mean arterial pressure (MAP). The infusion rate was adjusted to maintain HR in range of 60-80 beats/min and MAP in range of 65-75 mmHg.
Trial: NCT00000739
Drug: Dapsone
RxNorm normalized name: Dapsone
DrugBank: Dapsone (DB00250)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05385432
Drug: Rabbit Anti thymocyte globulin (rATG)
RxNorm normalized name: Rabbit anti-human thymocyte globulin (rATG)
DrugBank: Rabbit (DB10415)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The infusion of rTAG (Thymoglobulin® (1.5mg/kg/day, maximum daily dose: 100 mg)) starts just after the randomization pre-operatively on a functional arteriovenous fistula or a high-flow venous catheter during 3 to 7 days until efficient tacrolimus level is obtained.
Trial: NCT05385432
Drug: Basiliximab
RxNorm normalized name: Basiliximab
DrugBank: Basiliximab (DB00074)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Simulect® IV 40mg D0 and D4
Trial: NCT01028313
Drug: Methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 mg/kg/day PO continuously
Trial: NCT06598449
Drug: fenfluramine
RxNorm normalized name: fenfluramine
DrugBank: Fenfluramine (DB00574)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clear, cherry flavored oral solution
Trial: NCT06403709
Drug: Irinotecan, Trifluridine/tipiracil (TAS-102) plus Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: These patients received an intravenous infusion of irinotecan (150mg/m2 on day 1) plus bevacizumab (5 mg/kg on day 1) and an oral administration of TAS-102(30 mg/m2 given bid on days 1-5), repeated every 14 days.
Trial: NCT06440135
Drug: Ziftomenib
RxNorm normalized name: Ziftomenib
DrugBank: Ziftomenib (DB17171)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taken orally once per day
Trial: NCT03503058
Drug: Chloroquine chemoprophylaxis alone
RxNorm normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Loading Dose: 10 mg/kg of CQ base (will be orally administered as a single loading dose to the participant by the study staff via directly observed therapy on NS Day -2.~Weekly Dose: Subsequent doses of maintenance dose CQ (5 mg/kg CQ base) will be given weekly as a single dose, with the last dose 5 days after the last dose of NS.
Trial: NCT06433947
Drug: OPN-6602
RxNorm normalized name: anti-Tlr2 monoclonal antibody OPN-305
DrugBank: Tomaralimab (DB15415)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: orally active, small molecule inhibitor of EP300 and CBP bromodomain; dosed daily
Trial: NCT06433947
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Synthetic glucocorticoid; 40 mg Days 1, 8, 15 of each cycle
Trial: NCT06270108
Drug: Riluzole
RxNorm normalized name: Riluzole
DrugBank: Riluzole (DB00740)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50mg twice daily (100mg total daily) for 56 days.
Trial: NCT06326736
Drug: Camrelizumab
RxNorm normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Camrelizumab will be administered 6 weeks post-tumor resection.
Trial: NCT06326736
Drug: Gemcitabine+Abraxane
RxNorm normalized name: Abraxane
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine+Abraxane regimen will be administered 21 weeks post-tumor resection.
Trial: NCT06277674
Drug: Cadonilimab plus Pemetrexed and Anlotinib
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cadonilimab was administered intravenously at a dose of 10 mg/kg every 3 weeks. Pemetrexed was administered intravenously at a dose of 500 mg/m² every 3 weeks Anlotinib was taken at doses of 10mg orally once daily for two weeks on a one-week-off schedule.
Trial: NCT05550350
Drug: Dexycu
RxNorm normalized name: Dexycu
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 103.4 mcg/mcl dexamethasone: equivalent dexamethasone dose: 517 mcg
Trial: NCT04958876
Drug: Naltrexone immediate release oral capsules
RxNorm normalized name: morphine / naltrexone Extended Release Oral Capsule
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral capsule once daily
Trial: NCT05130047
Drug: Aldafermin
RxNorm normalized name: Aldafermin
DrugBank: Aldafermin (DB16086)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg solution
Trial: NCT00561366
Drug: Arimoclomol
RxNorm normalized name: arimoclomol
DrugBank: Arimoclomol (DB05025)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsule, 400 mg t.i.d.
Trial: NCT06000137
Drug: Dezocine
RxNorm normalized name: DEZOCINE
DrugBank: Dezocine (DB01209)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: dezocine for patient-controlled analgesia
Trial: NCT06000137
Drug: Granisetron Injection
RxNorm normalized name: granisetron Injection
DrugBank: Granisetron (DB00889)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: granisetron has antiemetic function.
Trial: NCT02354612
Drug: TRC105
RxNorm normalized name: IMMUNOGLOBULIN G1, ANTI-(HUMAN ENDOGLIN) (HUMAN-MUS MUSCULUS MONOCLONAL TRC105 HEAVY CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL TRC105 .KAPPA.-CHAIN, DIMER
DrugBank: Carotuximab (DB06322)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02354612
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: companion therapy selection depends on companion therapy used in the parent study